HR Execs on the Move


 
Alcami is a contract development and manufacturing organization headquartered in North Carolina with over 40 years of experience advancing products through every stage of the development lifecycle. Alcami serves pharmaceutical and biotech companies of all sizes for small molecules and biologics, providing customizable and innovative solutions for analytical development, clinical to commercial sterile and oral solid dose drug product manufacturing, packaging, microbiology, cGMP biostorage, environmental monitoring, and pharmaceutical support services. Alcami`s private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.alcami.com
  • 2320 Scientific Park Drive
    Wilmington, NC USA 28405
  • Phone: 910.254.7000

Executives

Name Title Contact Details
Gerry Glennon
Vice President of Global Supply Chain Profile
Rose-Marie Nelson
EVP, Talent Acquisition, Benefits and Profile
Rose-Marie Nelson
Chief Human Resources Officer Profile
Shelley Brinkley
Director Talent Acquisition Profile
Ken Morgan
Chief Financial Officer Profile

Similar Companies

Beth Israel Deaconess Hospital-Needham

BID Needham, part of Beth Israel Lahey Health, is focused on providing our patients with easy access to compassionate, safe and high-quality health care.

Zenabis Global

Zenabis is a significant Licensed Producer of medical and recreational cannabis, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, British Columbia; and Stellarton, Nova Scotia.

Constab Pharmaceuticals

Constab Pharmaceuticals is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cleveland Rape Crisis Center

Supporting survivors of sexual abuse and rape, promoting healing and prevention, and advocating for social change in Northeast Ohio

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.